JomCare Study - A Harm Reduction Study
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexMale
Age18+
SponsorUniversity of Connecticut
About this trial
Chemsex, the use of psychoactive drugs before or during sexual activity, is a growing public health concern associated with striking increases in HIV, particularly among men who have sex with men (MSM). This study proposes to optimize an app-based just-in-time adaptive intervention, called JomCare, which aims to reduce chemsex risk by delivering tailored support when a person is most likely to be vulnerable to chemsex risk behaviors and receptive to intervention, with the purpose of reducing risk and averting new HIV infections.
Eligibility criteria
Qualifiers
Age ≥18 years;
Cisgender man;
HIV-negative or HIV status unknown;
Having engaged in "chemsex" in the past 12 months (defined as using CAD, including crystal methamphetamine, mephedrone, GBL/GHB, and/or ecstasy/MDMA)
Disqualifiers
Unable to provide informed consent
Enrolled in drug rehabilitation, substance use treatment, and narcotics or other behavioral intervention-based treatment
Unable to read and understand English or Bahasa Malaysia
Trial design
Treatments tested in this trial
- JomCare is a smartphone-based just-in-time adaptive intervention (JITAI) for chemsex-related harm reduction.
Treatment groups
482 Participants
are divided into 5 treatment groupsSponsors and collaborators
University of Connecticut
Lead sponsor
University of Malaya
Collaborator
Yale University
Collaborator
National Institute on Drug Abuse (NIDA)
Collaborator
University of Michigan
Collaborator
University of Texas at Tyler
Collaborator
Ohio State University
Collaborator
Source ClinicalTrials.gov